Discussion
Treatment with Enspryng (satralizumab) was associated with fewer attacks and improved disability scores among people with neuromyelitis optica spectrum disorder (NMOSD) in a real-world study in China. The findings included patients who switched from other treatments. “Collectively, these findings extend current real-world evidence on [Enspryng] across clinically…